Press Releases

MILLERSBURG, Ohio--(BUSINESS WIRE)-- CSB Bancorp, Inc., (OTC Pink: CSBB) announced that the Company’s Board of Directors has declared a second quarter cash dividend of $0.39 per share on its common stock, payable June 18, 2024, to shareholders of record as of June 4, 2023.

CSB Bancorp, Inc. is a financial holding company headquartered in Millersburg, Ohio, with approximate assets of $1.2 billion as of March 31, 2024. CSB provides a complete range of banking and... (continue reading...)

PASADENA, Calif.--(BUSINESS WIRE)-- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases, today reported financial results for the first quarter ended March 31, 2024 and provided a review of recent clinical and business highlights.

“We have focused our XmAb® clinical pipeline and discovery activities on bispecific CD3 and CD28 T cell engagers, which... (continue reading...)

POWAY, Calif.--(BUSINESS WIRE)-- Cohu, Inc. (NASDAQ: COHU), a global supplier of equipment and services optimizing semiconductor manufacturing yield and productivity, today announced that management will participate at the following investor conferences:

B. Riley Securities 24th Annual Institutional Investor Conference Location: Beverly Hilton Hotel, Beverly Hills, CA May 23, 2024

TD Cowen 52nd Annual Technology, Media & Telecom Conference Location: Lotte Palace... (continue reading...)

GOOSE CREEK, SC / ACCESSWIRE / May 9, 2024 / HireQuest, Inc. (Nasdaq: HQI), a national franchisor of direct dispatch, executive search, and commercial staffing services, today reported financial results for the first quarter ended March 31, 2024.

First Quarter 2024 Summary

• Franchise royalties decreased 16.0% to $7.8 million compared to $9.3 million in the prior year period.
• Total revenue decreased 14.6% to $8.4 million compared to $9.9 million in the prior year... (continue reading...)

• INT230-6, Intensity's lead drug candidate, continues to advance into late-stage clinical programs in sarcoma and breast cancer
• Cash and investments of $10.5 million expected to fund operations through the end of the first quarter of 2025

SHELTON, Conn., May 9, 2024 /PRNewswire/ -- Intensity Therapeutics, Inc. ("Intensity" or "the Company") (Nasdaq: INTS), a late-stage clinical biotechnology company focused on the discovery and development of proprietary, novel... (continue reading...)